{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T19:27:08Z","timestamp":1788809228251,"version":"build-2803163510"},"reference-count":38,"publisher":"SAGE Publications","issue":"5","license":[{"start":{"date-parts":[[2009,10,1]],"date-time":"2009-10-01T00:00:00Z","timestamp":1254355200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Child and Adolescent Psychopharmacology"],"published-print":{"date-parts":[[2009,10]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Second-generation antipsychotics (SGAs) are associated with weight gain, metabolic abnormalities, sedation\/sleep disturbance, and prolactin abnormalities, especially in youths. Although stimulants have opposing dopamine receptor and adverse effects, it is unclear whether stimulant co-treatment counteracts the therapeutic or side effects of antipsychotics.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>\n                      This was a naturalistic cohort study including 153 antipsychotic trials in youths aged 4\u201319 (mean, 11.3 \u00b1 3.0) years, started on an SGA for clinically significant aggression or oppositionality associated with oppositional defiant disorder, conduct disorder, disruptive behavior disorder not otherwise specified (NOS), impulse control disorder NOS, intermittent explosive disorder, Tourette's disorder, autistic disorder, and pervasive developmental disorder NOS. Patients underwent fasting assessments of body composition, lipids, glucose, insulin, prolactin, sedation, and general efficacy at baseline, weeks 4, 8, and 12, comparing patients co-prescribed stimulants (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      \u2009=\u200971) with those not co-prescribed stimulants (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      \u2009=\u200982).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Patients received risperidone (33.3%), aripiprazole (29.4%), quetiapine (18.4%), olanzapine (11.8%), ziprasidone (5.9%), or clozapine (0.7%). With and without adjustment for differences in baseline variables (sex, prior stimulant use, primary\n                      <jats:italic toggle=\"yes\">Diagnostic and Statistical Manual of Mental Disorders<\/jats:italic>\n                      , 4\n                      <jats:sup>th<\/jats:sup>\n                      edition [DSM-IV] disorders, co-morbid attention-deficit\/hyperactivity disorder [ADHD], present in 46.3% of youths not receiving stimulants, and some body composition parameters), patients on versus off stimulants did not differ on any of the assessed outcomes (all\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      values\u2009\u2265\u20090.1).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>In contrast to guidelines, stimulant use did not precede or accompany antipsychotic use during the current episode of aggression\/oppositionality in almost half of those youths who had aggressive\/oppositional behavior and a DSM-IV diagnosis of ADHD. At the clinically prescribed doses, stimulant co-treatment of SGAs did not seem to significantly reduce antipsychotic effects on body composition, metabolic parameters, prolactin, sedation, and broad efficacy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1089\/cap.2009.0051","type":"journal-article","created":{"date-parts":[[2009,10,30]],"date-time":"2009-10-30T18:59:33Z","timestamp":1256929173000},"page":"563-573","source":"Crossref","is-referenced-by-count":48,"title":["Lack of Effect of Stimulant Combination with Second-Generation Antipsychotics on Weight Gain, Metabolic Changes, Prolactin Levels, and Sedation in Youth with Clinically Relevant Aggression or Oppositionality"],"prefix":"10.1177","volume":"19","author":[{"given":"Julie B.","family":"Penzner","sequence":"first","affiliation":[{"name":"NewYork-Presbyterian Hospital\/Weill Cornell Medical College"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Dudas","sequence":"additional","affiliation":[{"name":"The Zucker Hillside Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ema","family":"Saito","sequence":"additional","affiliation":[{"name":"The Zucker Hillside Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vladimir","family":"Olshanskiy","sequence":"additional","affiliation":[{"name":"The Zucker Hillside Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Umesh H.","family":"Parikh","sequence":"additional","affiliation":[{"name":"The Zucker Hillside Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandeep","family":"Kapoor","sequence":"additional","affiliation":[{"name":"The Zucker Hillside Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raja","family":"Chekuri","sequence":"additional","affiliation":[{"name":"The Zucker Hillside Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominick","family":"Gadaleta","sequence":"additional","affiliation":[{"name":"The Zucker Hillside Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Avedon","sequence":"additional","affiliation":[{"name":"The Zucker Hillside Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva M.","family":"Sheridan","sequence":"additional","affiliation":[{"name":"The Zucker Hillside Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane","family":"Randell","sequence":"additional","affiliation":[{"name":"The Zucker Hillside Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anil K.","family":"Malhotra","sequence":"additional","affiliation":[{"name":"The Zucker Hillside Hospital"},{"name":"Albert Einstein College of Medicine"},{"name":"The Feinstein Institute for Medical Research"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John M.","family":"Kane","sequence":"additional","affiliation":[{"name":"The Zucker Hillside Hospital"},{"name":"Albert Einstein College of Medicine"},{"name":"The Feinstein Institute for Medical Research"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph U.","family":"Correll","sequence":"additional","affiliation":[{"name":"The Zucker Hillside Hospital"},{"name":"Albert Einstein College of Medicine"},{"name":"The Feinstein Institute for Medical Research"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2009,10,1]]},"reference":[{"key":"e_1_3_2_2_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.159.8.1337"},{"key":"e_1_3_2_3_1","doi-asserted-by":"publisher","DOI":"10.1089\/1044546041649020"},{"key":"e_1_3_2_4_1","unstructured":"American Psyschiatric Association. Diagnostic Statistical Manual of Mental Disorders 4th edition(DMX-IV) Washington (DC): American Psychiatric Association 1994."},{"key":"e_1_3_2_5_1","first-page":"214","article-title":"Child psychiatric disorders among primary mental health service attenders","volume":"53","author":"Arcelus J","year":"2003","unstructured":"Arcelus J, , Vostanis P. Child psychiatric disorders among primary mental health service attenders. Br J Gen Pract, 53:214\u2013216. 2003.","journal-title":"Br J Gen Pract"},{"key":"e_1_3_2_6_1","doi-asserted-by":"publisher","DOI":"10.1097\/chi.0b013e3180323354"},{"key":"e_1_3_2_7_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF01670101"},{"key":"e_1_3_2_8_1","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.150.12.1900"},{"key":"e_1_3_2_9_1","doi-asserted-by":"publisher","DOI":"10.1089\/cap.2008.007"},{"key":"e_1_3_2_10_1","doi-asserted-by":"publisher","DOI":"10.1097\/chi.0b013e31815b5cb1"},{"key":"e_1_3_2_11_1","first-page":"26","article-title":"Assessing and maximizing the safety and tolerability of antipsychotics used in the treatment of children and adolescents","volume":"69","author":"Correll CU","year":"2008","unstructured":"Correll CU. Assessing and maximizing the safety and tolerability of antipsychotics used in the treatment of children and adolescents. J Clin Psychiatry, 69:26\u201336. 2008b.","journal-title":"J Clin Psychiatry"},{"key":"e_1_3_2_12_1","doi-asserted-by":"publisher","DOI":"10.1080\/09540260801889179"},{"key":"e_1_3_2_13_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.chi.0000220851.94392.30"},{"key":"e_1_3_2_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.chc.2005.08.007"},{"key":"e_1_3_2_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-5618.2007.00487.x"},{"key":"e_1_3_2_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/1469-7610.00786"},{"key":"e_1_3_2_17_1","doi-asserted-by":"publisher","DOI":"10.1097\/CHI.ObO13e31817eOea7"},{"key":"e_1_3_2_18_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v64n1113"},{"key":"e_1_3_2_19_1","first-page":"223","volume-title":"ECDEU Assessment Manual for Psychopharmacology. Department of Health, Education and Welfare publication ABM 76\u2013338","author":"Guy W","year":"1976","unstructured":"Guy W. ECDEU Assessment Manual for Psychopharmacology. Department of Health, Education and Welfare publication ABM 76\u2013338. Washington (DC): US Government Printing Office, 223\u201341. 1976."},{"key":"e_1_3_2_20_1","doi-asserted-by":"publisher","DOI":"10.1089\/cap.2007.0098"},{"key":"e_1_3_2_21_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00787-006-0580-1"},{"key":"e_1_3_2_22_1","doi-asserted-by":"publisher","DOI":"10.1089\/cap.2006.0012"},{"key":"e_1_3_2_23_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc06-0709"},{"key":"e_1_3_2_24_1","doi-asserted-by":"publisher","DOI":"10.1097\/00004583-200012000-00007"},{"key":"e_1_3_2_25_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v64n0420h"},{"key":"e_1_3_2_26_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF00280883"},{"key":"e_1_3_2_27_1","doi-asserted-by":"publisher","DOI":"10.1017\/S0954579408000424"},{"key":"e_1_3_2_28_1","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.153.9.1231b"},{"key":"e_1_3_2_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-7610.2007.01733.x"},{"key":"e_1_3_2_30_1","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.63.6.679"},{"key":"e_1_3_2_31_1","doi-asserted-by":"publisher","DOI":"10.1097\/00004583-200302000-00008"},{"key":"e_1_3_2_32_1","first-page":"27","article-title":"Pharmacotherapy of aggression in children, adolescents: Efficacy and effect size","volume":"15","author":"Pappadopulos E","year":"2006","unstructured":"Pappadopulos E, , Woolston S, , Chait A, , Perkins M, , Connor DF, , Jensen PS. Pharmacotherapy of aggression in children, adolescents: Efficacy and effect size. J Can Acad Child Adolesc Psychiatry, 15:27\u201339. 2006.","journal-title":"J Can Acad Child Adolesc Psychiatry"},{"key":"e_1_3_2_33_1","first-page":"642","article-title":"Texas Consensus Conference Panel on Pharmacotherapy of Childhood Attention Deficit Hyperactivity Disorder","volume":"45","author":"Pliszka SR","year":"2006","unstructured":"Pliszka SR, , Crismon ML, , Hughes CW, , Corners CK, , Emslie GJ, , Jensen PS, , McCracken JT, , Swanson JM, , Lopez M. Texas Consensus Conference Panel on Pharmacotherapy of Childhood Attention Deficit Hyperactivity Disorder. The Texas Children's Medication Algorithm Project: Revision of the algorithm for pharmacotherapy of attention-deficit\/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry, 45:642\u2013657. 2006.","journal-title":"The Texas Children's Medication Algorithm Project: Revision of the algorithm for pharmacotherapy of attention-deficit\/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry"},{"key":"e_1_3_2_34_1","doi-asserted-by":"publisher","DOI":"10.1097\/00004583-200302000-00007"},{"key":"e_1_3_2_35_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v66n0705"},{"key":"e_1_3_2_36_1","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1983.01790100074010"},{"key":"e_1_3_2_37_1","doi-asserted-by":"publisher","DOI":"10.1097\/00004583-200209000-00002"},{"key":"e_1_3_2_38_1","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.56.12.1073"},{"key":"e_1_3_2_39_1","doi-asserted-by":"publisher","DOI":"10.1542\/peds.110.3.e34"}],"container-title":["Journal of Child and Adolescent Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/cap.2009.0051","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/cap.2009.0051","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/cap.2009.0051","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T14:54:38Z","timestamp":1777388078000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1089\/cap.2009.0051"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,10]]},"references-count":38,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2009,10]]}},"alternative-id":["10.1089\/cap.2009.0051"],"URL":"https:\/\/doi.org\/10.1089\/cap.2009.0051","relation":{},"ISSN":["1044-5463","1557-8992"],"issn-type":[{"value":"1044-5463","type":"print"},{"value":"1557-8992","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,10]]}}}